304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2024-10-24

First Patient in Japan Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2024-10-23

HLX22 Dual HER2 Blockade Therapy Featured on the Cover of Med
2024-10-21

Henlius Receives Approval in Japan for Phase 3 MRCT of Dual HER2 Blockade Therapy on First-Line HER2+ GC
2024-10-14

Henlius Shines at CPHI Worldwide 2024, Expanding New Opportunities for International Collaboration
2024-09-30

Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
2024-09-21

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
2024-09-18

Latest Results of HANSIZHUANG and HANQUYOU Released at 2024 ESMO
2024-09-13

Meet Henlius at CPHI Worldwide 2024
2024-09-09

Latest Results of Serplulimab in the Field of SCLC Released at 2024 WCLC